Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at 0 times
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
- The company has been able to generate a Return on Equity (avg) of 13.85% signifying low profitability per unit of shareholders funds
2
Healthy long term growth as Operating profit has grown by an annual rate 37.00%
3
The company has declared Positive results for the last 4 consecutive quarters
4
With ROE of 18.3, it has a attractive valuation with a 5 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
PKR 15,488 Million (Small Cap)
21.00
NA
0.62%
0.14
22.19%
4.13
Revenue and Profits:
Net Sales:
2,536 Million
(Quarterly Results - Mar 2025)
Net Profit:
91 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.67%
0%
12.67%
6 Months
-3.93%
0%
-3.93%
1 Year
306.42%
0%
306.42%
2 Years
268.06%
0%
268.06%
3 Years
218.22%
0%
218.22%
4 Years
175.79%
0%
175.79%
5 Years
319.67%
0%
319.67%
Macter International Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.16%
EBIT Growth (5y)
32.53%
EBIT to Interest (avg)
7.25
Debt to EBITDA (avg)
1.07
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
2.23
Tax Ratio
42.52%
Dividend Payout Ratio
22.42%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
19.71%
ROE (avg)
13.85%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
4.70
EV to EBIT
13.73
EV to EBITDA
11.90
EV to Capital Employed
4.12
EV to Sales
1.70
PEG Ratio
0.21
Dividend Yield
0.05%
ROCE (Latest)
30.04%
ROE (Latest)
22.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
2,535.60
2,885.00
-12.11%
Operating Profit (PBDIT) excl Other Income
293.90
552.50
-46.81%
Interest
32.80
31.50
4.13%
Exceptional Items
0.00
-23.30
100.00%
Consolidate Net Profit
91.20
308.50
-70.44%
Operating Profit Margin (Excl OI)
86.70%
169.00%
-8.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -12.11% vs 27.74% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -70.44% vs 248.98% in Dec 2024
Annual Results Snapshot (Consolidated) - Jun'24
Jun'24
Jun'23
Change(%)
Net Sales
7,974.50
6,926.10
15.14%
Operating Profit (PBDIT) excl Other Income
922.80
727.90
26.78%
Interest
126.00
72.50
73.79%
Exceptional Items
-8.10
5.20
-255.77%
Consolidate Net Profit
402.20
348.80
15.31%
Operating Profit Margin (Excl OI)
83.10%
74.70%
0.84%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2024 is 15.14% vs 23.42% in Jun 2023
Consolidated Net Profit
YoY Growth in year ended Jun 2024 is 15.31% vs 21.96% in Jun 2023
About Macter International Ltd. 
Macter International Ltd.
Pharmaceuticals & Biotechnology
Macter International Ltd is a Pakistan-based pharmaceutical company. The Company’s primary activity is to manufacture and market pharmaceutical products. It offers a diversified portfolio of pharmaceutical products covering all therapeutic categories including antibiotics, anti-allergy, cardiovascular and Anti-viral infections. Its offered product under various therapeutic categories, includes DX3 Softgel, Macdronic 5mg, Macdronic 4mg , MAclimta , Milast, MACIVY, MACLINZA, Avelia Sachet, SANTE IV, Maclusa, Nurica, Alenor, Atizox, Bismol, Buphain, Cadla, Carac, Carac-H, Co-Amoxi, Dexodine, Demeco, Dicaine, DX3 Softgel, Ecavir, Epilepsin, Epuram, Esante, Glio, Hart, Heberon Alfa R, Inspirol, Itogaurd, Lefanor, Locril, Locril Plus, Mac-Mether, Macprofen, Macdicol, Macticort, Mitaz, Proberry Probiotic Capsule, Sante Plus, Setzine, Sofomac, Tacip, tio-Veez and Zincasa.
Company Coordinates 
Company Details
F-216, S.I.T.E , KARACHI None : 75700
Registrar Details






